Pulse Biosciences Posts 96% Success Rate at 1-Year for Novel Heart Ablation Tech

Pulse Biosciences Inc. (Nasdaq: PLSE) reported a 96% procedural success rate at one year for its nPulse cardiac catheter system in treating atrial fibrillation, positioning its novel nanosecond pulsed-field ablation (nsPFA) technology as a strong future competitor in a market currently dominated by giants like Medtronic and Abbott.

"These 12-month results are genuinely impressive," said principal investigator Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital. "The durability of pulmonary vein isolation combined with the procedural efficiency we're seeing is not something we typically expect together at this stage of development."

The updated results from the first-in-human study, presented at the Heart Rhythm 2026 meeting, showed 100% procedural success in 95 patients at six months and 96% success (51 of 53 patients) at 12 months. The system demonstrated efficient performance with an average total procedure time of just 60.2 minutes and a low serious adverse event rate of 1.7% across 177 total patients.

The positive data could significantly de-risk the nPulse system as it moves toward regulatory approval, targeting a multi-billion dollar atrial fibrillation ablation market. While Pulse Biosciences is smaller than competitors like Boston Scientific with its Farapulse system or Johnson & Johnson's Varipulse, the high success and safety profile could allow it to capture significant market share upon commercialization.

The data, an expansion of results presented at the AF Symposium in February 2026, reinforces the potential of nsPFA as a differentiated, non-thermal ablation modality. Unlike traditional radiofrequency ablation which uses heat, or competing PFA systems, Pulse's technology uses nanosecond-duration electrical pulses designed to clear cells non-thermally while sparing adjacent tissue. This may contribute to the low 1.7% rate of serious adverse events observed in the study.

The procedural efficiency metrics stand out in a competitive field. The average left atrial dwell time of 18.6 minutes and total procedure time of roughly one hour suggest a streamlined workflow for electrophysiologists. This speed, combined with durability, is a key focus in the evolving PFA landscape, where Medtronic's PulseSelect, Abbott's Volt, and Boston Scientific's Farapulse are all vying for physician adoption. Abbott also recently presented positive data for its own dual-energy TactiFlex Duo catheter, highlighting the intense innovation in the sector.

For investors, Pulse Biosciences represents a high-risk, high-reward play in the medical device space. The company's stock (PLSE) is highly sensitive to clinical data, and these durable 12-month results provide a critical validation point. While the company's revenue and market share are not yet established, the technology's performance against a backdrop of multi-billion dollar incumbents suggests a significant potential valuation uplift if the nPulse system successfully navigates the path to commercial approval in the US and Europe. The next major catalyst will be the company's discussions with regulators and the potential initiation of a pivotal trial.

This article is for informational purposes only and does not constitute investment advice.